STAB2 and hepatocellular carcinoma: During hepatocellular carcinoma (HCC) progression in humans, LSECs lose the expression of their markers, including lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), CD32b, stabilin-1, and stabilin-2 [327].